发布时间：2008.6

摘要

Leading Drug Delivery Companies and Technologies Competitive landscape, company profiles and technological developments

Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report...

• The oral delivery system continues to dominate the drug delivery market due to convenient usage, cost-effectiveness and low frequency of administration. Needleless injectables, PEGylation technologies and micro-electromechanical devices are among the novel technologies with the greatest growth potential.
• The market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems will grow, due to the ease of administration and resistance to infections associated with these methods. The needle-free delivery sector will rise to $3bn by 2010.
• Pulmonary delivery technologies are increasingly prevalent in pain management, cystic fibrosis and diabetes. Pulmonary-based delivery vehicles are currently the focus of a number of major companies including Nektar, Aradigm, 3M, and Alkermes.
• Dry powder inhalers will secure the largest share of sales within the asthma market, as demand for treatments in this therapy area continues to expand. However, MDI products will experience a relatively higher rate of growth due to consistent improvements in particle size and safe propellant delivery.

Leading Drug Delivery Companies and Technologies Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000-2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues. Although the market is still dominated by the oral drug delivery system, a number of novel technologies are emerging across all systems of delivery. However, the pure drug delivery company model is rapidly becoming extinct as leading players attempt to consolidate their strategic opportunities by expanding their focus towards manufacturing, a trend that is expected to accelerate over the next five years.

‘Leading Drug Delivery Companies and Technologies’ is a new report published by Business Insights that examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations.

Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their strategies with this new report...

Top reasons to order your copy today

• Discover the key issues and trends in the global drug delivery market with this report’s analysis of market size and growth, the commercial value of drug delivery systems and the extended strategic focus of growing numbers of drug delivery companies.
• Identify the dynamics of major drug delivery systems by evaluating the latest market developments and technological innovations in oral, pulmonary, injectable and transdermal delivery platforms.
• Assess the leading players in the drug delivery market with this report’s review of the opportunities and threats, financial performances and R&D expenditures of Biovail, Elan, SkyePharma, Alkermes, Bioject, QLT, Nektar, Aradigm, Antares, Noven, Alza and 3M.
• Benchmark the strategies of leading drug delivery companies by evaluating their product portfolios and pipelines, deals and alliances, targeted therapeutic areas and technology platforms

Key issues examined in this report...

• Technology driving growth. Drug delivery technologies are being used to boost revenues and enhance product efficacy by developing future commercial opportunities and expanding product lifecycles.
• Expanding strategic focus. A growing number of drug delivery companies are evolving into specialty pharma companies. Widening the core business to incorporate manufacturing is a strategy increasingly used to enhance revenues.
• Stagnant R&D investment. The companies featured in this report recorded an average growth in R&D expenditure of just 6% during 2003-2007. This low growth in R&D spend is likely to inhibit the discovery and development of new products in the short term.
• Inhaled insulin setback. The development of inhaled insulin has been the focus of many companies operating in the pulmonary drug delivery field. However, a high number late-stage terminations have raised doubts over the commercial potential of this delivery vehicle.

Your questions answered...

• What are the major issues surrounding drug delivery within the global pharma industry?
• What are the latest innovations and developments in different drug delivery vehicles?
• What are the market dynamics for oral, injectable, pulmonary and transdermal drug delivery systems?
• What are the key technologies and growth strategies of leading drug delivery companies?
• What are the product portfolios, pipeline candidates, financial performances and R&D expenditures of these leading companies?
• What opportunities and threats will drug delivery companies face in the future?

目录及图表

Leading Drug Delivery Companies and Technologies

Executive Summary

Overview on drug delivery industry

Oral drug delivery system

Injectable drug delivery system

Pulmonary drug delivery system

Transdermal drug delivery system

Chapter 1 Overview of drug delivery

industry

Summary

What is this report about?

Methodology

Drug delivery overview

Role of drug delivery in the pharma landscape

Revenue boosters for pharma companies

Patent extension and protection from generic competition

Reformulation of existing products

Optimizing returns on R&D investment

Compliance, bioavailability and safety benefits

From drug delivery to specialty pharma

Markets for drug delivery systems

Oral drug delivery system

Pulmonary

Injectable

Transdermal

Market dynamics

Chapter 2 Oral drug delivery system

Summary

Synopsis

Oral drug delivery technologies

Technologies for fast-dissolving and taste-masking pills

Controlled oral drug delivery

Types of controlled release

Dynamics of oral drug delivery market

Biovail

Key technologies

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Expanding its presence in diverse geographical areas

Deriving growth from strategic alliances

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Elan

Key technologies

NanoCrystal technology

OCR technology

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Alzheimer’s disease

Pipeline products

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

SkyePharma

Key technologies

Oral drug delivery technologies

Inhalation technologies

Insoluble drug delivery (IDD) technology

Therapeutic focus

Products portfolio and pipeline candidates

Recent financial performance

Growth strategies

Focus on building pipeline of products

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Chapter 3 Injectable drug delivery system

Summary

Synopsis

Injectable drug delivery technologies

Needleless injection device technology

Sustained/controlled release technology

PEGylation

Therapeutic focus

Dynamics of the injectable drug delivery market

Alkermes

Introduction

Key technologies

Medisorb injectable technology

AIR pulmonary drug delivery technology

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Bioject

Introduction

Key technologies

Needle-free injection technology

Therapeutic Focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Developing clinical research collaborations

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

QLT

Key technologies

Atrigel drug delivery system

PDT

Therapeutic focus

Product portfolio and pipeline candidates

Recent company financials

Growth strategies

Focus on key therapeutic areas

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Chapter 4 Pulmonary drug delivery system

Summary

Synopsis

Inhaled formulations

Therapeutic focus

Dynamics of the pulmonary drug delivery market

Nektar Therapeutics

Key technologies

Dry powder pulmonary technology

Liquid pulmonary technology

PEGylation technology

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Shifting focus from drug delivery to become a specialty pharma

company

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Aradigm

Key technologies

AERx pulmonary drug delivery system

Liposomal Formulations

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

3M

Key technologies

Pulmonary drug delivery technology

Transdermal drug delivery technology

Therapeutic focus

Product portfolio and pipeline candidates

Growth strategies

Deals and alliances

Chapter 5 Transdermal drug delivery system

Summary

Synopsis

Transdermal drug delivery technologies

Passive formulations

Active formulations

Therapeutic focus

Dynamics of the transdermal drug delivery market

Antares

Key technologies

Advanced transdermal delivery

Injection devices

Easy Tec fast melt oral disintegrating tablets

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Noven

Key technologies

DOT Matrix technology

Therapeutic focus

Product portfolio and pipeline candidates

Recent financial performance

Growth strategies

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Alza

Key technologies

D-Trans

E-Trans

Macroflux

Stealth

Alzamer

Oros

Therapeutic focus

Product portfolio and pipeline candidate

Deals and alliances

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Chapter 6 Conclusion

Financials

Growth strategies

Outlook

Glossary

Index

List of Figures

Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies

Figure 1.2: Procardia XL patent expiry

Figure 1.3: Cardizem’s reformulation strategy

Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery

Figure 1.5: Positioning of key drug delivery companies

Figure 1.6: Key drug delivery systems market share, 2006

Figure 2.7: Biovail financial performance, $m, 2003-2007

Figure 2.8: Biovail SWOT analysis

Figure 2.9: Elan financial performance, 2003-2007 ($m)

Figure 2.10: Elan SWOT analysis

Figure 2.11: SkyePharma financial performance, $m, 2003-2007

Figure 2.12: SkyePharma SWOT analysis

Figure 3.13: Alkermes financial performance, 2003-2007

Figure 3.14: Alkermes SWOT analysis

Figure 3.15: Bioject financial performance, 2003-2007 ($m)

Figure 3.16: Bioject SWOT analysis

Figure 3.17: QLT financial performance, 2003-2007 ($m)

Figure 3.18: QLT SWOT analysis

Figure 4.19: Nektar financial performance, 2003-2007 ($m)

Figure 4.20: Nektar SWOT analysis

Figure 4.21: Aradigm financial performance, 2003-2007 ($m)

Figure 4.22: Aradigm SWOT analysis

Figure 5.23: Antares financial performance, 2003-2007 ($m)

Figure 5.24: Antares SWOT analysis

Figure 5.25: Noven financial performance, 2003-2007 ($m)

Figure 5.26: Noven SWOT analysis

Figure 5.27: Alza SWOT analysis

Figure 6.28: Comparative analysis of key drug delivery companies (I)

Figure 6.29: Comparative analysis of key drug delivery companies (II)

List of Tables

Table 2.1: Biovail snapshot

Table 2.2: Biovail oral marketed products

Table 2.3: Biovail oral product sales, 2006-2007 ($m)

Table 2.4: Biovail oral product pipeline

Table 2.5: Biovail financial performance, 2003-2007 ($m)

Table 2.6: Elan snapshot

Table 2.7: Elan oral marketed products

Table 2.8: Elan NanoCrystal product pipeline

Table 2.9: Elan financial performance, 2003-2007 ($m)

Table 2.10: SkyePharma snapshot

Table 2.11: SkyePharma oral marketed products

Table 2.12: Skye Pharma oral product pipeline

Table 2.13: SkyePharma financial performance, 2003-2007

Table 3.14: Alkermes snapshot

Table 3.15: Alkermes injectable marketed products

Table 3.16: Alkermes injectable product sales, 2006-2007 ($m)

Table 3.17: Alkermes injectable product pipeline

Table 3.18: Alkermes financial performance, 2003-2007 ($m)

Table 3.19: Bioject snapshot

Table 3.20: Bioject injectable marketed products

Table 3.21: Bioject injectable product sales, 2006-2007 ($m)

Table 3.22: Bioject financial performance, 2003-2007 ($m)

Table 3.23: QLT snapshot

Table 3.24: QLT injectable marketed products

Table 3.25: QLT injectable product sales, 2006-2007 ($m)

Table 3.26: QLT injectable product pipeline

Table 3.27: QLT financial performance, 2003-2007 ($m)

Table 4.28: Nektar snapshot

Table 4.29: Nektar pulmonary marketed products

Table 4.30: Nektar pulmonary product sales, 2006-2007 ($m)

Table 4.31: Nektar pulmonary product pipeline

Table 4.32: Nektar financial performance, 2003-2007 ($m)

Table 4.33: Aradigm snapshot

Table 4.34: Aradigm pulmonary product pipeline

Table 4.35: Aradigm financial performance, 2003-2007 ($m)

Table 4.36: 3M snapshot

Table 4.37: 3M pulmonary marketed products

Table 5.38: Antares snapshot

Table 5.39: Antares transdermal marketed products

Table 5.40: Antares transdermal product pipleine

Table 5.41: Antares financial performance, 2003-2007 ($m)

Table 5.42: Noven snapshot

Table 5.43: Noven transdermal marketed products

Table 5.44: Noven transdermal product pipeline

Table 5.45: Noven financial performance, 2003-2007 ($m)

Table 5.46: Alza snapshot

Table 5.47: Alza transdermal marketed products